{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:12:05Z","timestamp":1791573125251,"version":"4.3.4"},"reference-count":80,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"20","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,7,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cancer treatment is evolving from organ-based classification toward biomarker-driven precision medicine, culminating in the development of tumor-agnostic therapies approved based on molecular characteristics, irrespective of tumor origin. Since the US Food and Drug Administration's landmark 2017 approval of pembrolizumab for microsatellite instability-high tumors, nine tumor-agnostic drugs have been approved, offering unprecedented treatment options for patients with rare cancers and actionable genomic alterations. However, this scientific breakthrough has revealed profound global implementation challenges. We reviewed the current landscape of tumor-agnostic drug approvals, regulatory pathways, and implementation experiences across multiple regions, including Europe, Asia-Pacific, Latin America, Africa, and the Middle East. Barriers to access were examined across regulatory, reimbursement, infrastructure, and workforce domains to inform a conceptual framework for implementation. Access remains inconsistent even in high-resource settings, with fewer than 50% of eligible patients receiving matched therapies. In Europe, centralized regulatory approval through the European Medicines Agency contrasts sharply with fragmented national reimbursement decisions, creating delays in access. Asia-Pacific nations demonstrate rapid growth in tumor-agnostic approvals and drug development capacity, although significant urban-rural disparities persist. Latin America, Africa, and areas in the Middle East face fundamental barriers, including limited testing infrastructure, workforce shortages, and competing health care priorities. To address these challenges, we propose a four-pillar framework for equitable implementation: comprehensive biomarker testing capability, innovative clinical trial designs with decision-support systems, harmonized regulatory approval and reimbursement mechanisms, and investment in genomically competent workforce development. International initiatives including Project Orbis and cross-border trial consortia demonstrate promising models for regulatory convergence. Realizing the transformative potential of tumor-agnostic therapies requires coordinated global strategies that bridge the divide between genomic innovation and geographic accessibility, ensuring all patients benefit regardless of socioeconomic status or location.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-26-00034","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:59:15Z","timestamp":1780343955000},"page":"1933-1944","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-6516","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"first","affiliation":[{"name":"The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia"},{"name":"Garvan Institute of Medical Research, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-0549","authenticated-orcid":false,"given":"Juliana","family":"Beal","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-9528","authenticated-orcid":false,"given":"Niamh","family":"Coleman","sequence":"additional","affiliation":[{"name":"Trinity St. James's Cancer Institute, Dublin, Ireland"},{"name":"Medical Oncology Department, St. James's Hospital, Dublin, Ireland"},{"name":"School of Medicine, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-1102","authenticated-orcid":false,"given":"Brigette B.Y.","family":"Ma","sequence":"additional","affiliation":[{"name":"Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong, China"},{"name":"Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-1106","authenticated-orcid":false,"given":"Herbert H.","family":"Loong","sequence":"additional","affiliation":[{"name":"Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong, China"},{"name":"Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-3888","authenticated-orcid":false,"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Sun Yat-Sen University Cancer Centre, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-0799","authenticated-orcid":false,"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group, Queens University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-3754","authenticated-orcid":false,"given":"Christoph Benedikt","family":"Westphalen","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Munich and Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"Istituto Europeo di Oncologia, IRCCS, Milano, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Early-Phase Drug Development, Sarah Cannon Research Institute (SCRI), Nashville, TN"},{"name":"Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_173855"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0384-0"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21844"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60369-1"},{"key":"e_1_3_5_6_2","article-title":"Rethinking cancer drug development through tumor-agnostic precision medicine","volume":"1","author":"Subbiah V","year":"2025","unstructured":"Subbiah V: Rethinking cancer drug development through tumor-agnostic precision medicine. Cancer Discov OF1-OF7, 2025","journal-title":"Cancer Discov"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00216-3"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00322-5"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2023.12.001"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.730"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30671-0"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.016"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1340"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"e_1_3_5_17_2","unstructured":"Merck: European Commission approved Merck\u2019s Keytruda (pembrolizumab) for patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in five different types of cancer. News Release 2022"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100145"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00337-5"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00714-2"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf015"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57941-0"},{"key":"e_1_3_5_23_2","article-title":"Precision oncology: A global perspective on implementation and policy development","author":"Horgan D","unstructured":"Horgan D, Tanner M, Aggarwal C, et al: Precision oncology: A global perspective on implementation and policy development. JCO Glob Oncol 10.1200\/GO-24-00416","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00541-1"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3334"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.021"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02379-4"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2390821"},{"key":"e_1_3_5_30_2","article-title":"Use of next-generation sequencing tests to guide cancer treatment: Results from a nationally representative survey of oncologists in the United States","author":"Freedman AN","unstructured":"Freedman AN, Klabunde CN, Wiant K, et al: Use of next-generation sequencing tests to guide cancer treatment: Results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol 10.1200\/PO.18.00169","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12687-019-00428-5"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01534"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.014"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000568"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.08.725"},{"key":"e_1_3_5_36_2","unstructured":"Italian Medicines Agency (AIFA): AIFA redefines the criteria for awarding the \u201cinnovativeness status\u201d to medicines. https:\/\/www.aifa.gov.it\/en\/-\/aifa-ridefinisce-criteri-attribuzione-innovativita"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105810"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.34885"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03918-x"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105902"},{"key":"e_1_3_5_41_2","first-page":"274","article-title":"Chinese expert consensus on the analytical validation of tumor comprehensive genomic profiling next generation sequencing testing","volume":"46","author":"Molecular Pathology Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association","year":"2024","unstructured":"Molecular Pathology Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association, Molecular Pathology Group of Chinese Society of Pathology: Chinese expert consensus on the analytical validation of tumor comprehensive genomic profiling next generation sequencing testing. Zhonghua Zhong Liu Za Zhi 46:274-284, 2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0142"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12338-y"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa277"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03044-0"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02267-y"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12630"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.06.04"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.920"},{"key":"e_1_3_5_51_2","first-page":"e10","article-title":"Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries","volume":"45","author":"Duran CE","year":"2021","unstructured":"Duran CE, Canas M, Urtasun MA, et al: Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries. Rev Panam Salud Publica 45:e10, 2021","journal-title":"Rev Panam Salud Publica"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1377"},{"key":"e_1_3_5_53_2","article-title":"African Consortium for Cancer Clinical Trials: Assessing, profiling, and building cancer clinical trial capacity in Africa","author":"Seymour D","unstructured":"Seymour D, Graef K, Dent J: African Consortium for Cancer Clinical Trials: Assessing, profiling, and building cancer clinical trial capacity in Africa. JCO Glob Oncol 10.1200\/GO.20.59000","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_5_54_2","article-title":"Oncology therapy access in the era of personalized medicine: Trends in regulatory approval and reimbursement for select countries in the Middle East and Africa","author":"IQVIA Institute for Human Data Science","year":"2025","unstructured":"IQVIA Institute for Human Data Science: Oncology therapy access in the era of personalized medicine: Trends in regulatory approval and reimbursement for select countries in the Middle East and Africa. IQVIA Institute Reports, 2025","journal-title":"IQVIA Institute Reports"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-23-25"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00425-x"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0257"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.709"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01081-w"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102703"},{"key":"e_1_3_5_61_2","unstructured":"Rare Cancers Australia: Now it\u2019s personal\u2014Access and equity for all. https:\/\/www.rarecancers.org.au\/wp-content\/uploads\/2025\/08\/RCA_Now-its-personal_Report.pdf"},{"key":"e_1_3_5_62_2","volume-title":"Expedited Programs for Serious Conditions\u2014Drugs and Biologics: Guidance for Industry","author":"US Food and Drug Administration","year":"2014","unstructured":"US Food and Drug Administration: Expedited Programs for Serious Conditions\u2014Drugs and Biologics: Guidance for Industry. Silver Spring, MD, U.S. Department of Health and Human Services FaDA, 2014"},{"key":"e_1_3_5_63_2","volume-title":"Guidance for Applicants Seeking Access to the PRIME Scheme (PRIority MEdicines)","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency: Guidance for Applicants Seeking Access to the PRIME Scheme (PRIority MEdicines). Amsterdam, the Netherlands, European Medicines Agency, 2016"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1177\/00469580231170729"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.921093"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-023-00522-4"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00286-9"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100635"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00701-X"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00158-X"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae060"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50741"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00530-3"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2639"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.001"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3292"},{"key":"e_1_3_5_79_2","volume-title":"Health at a Glance: Europe 2024: State of Health in the EU Cycle","author":"OECD\/European Commission","year":"2024","unstructured":"OECD\/European Commission: Health at a Glance: Europe 2024: State of Health in the EU Cycle. Paris, France, OECD Publishing, 2024"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02522-1"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","unstructured":"Childs S Ma D Houghton E et al: A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases. NPJ Precis Oncol 10.1038\/s41698-026-01462-6 [epub ahead of print on May 7 2026]","DOI":"10.1038\/s41698-026-01462-6"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-26-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:59:36Z","timestamp":1783634376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-26-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":80,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,7,10]]}},"alternative-id":["10.1200\/JCO-26-00034"],"URL":"https:\/\/doi.org\/10.1200\/jco-26-00034","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"2026-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}